Exodus Point Capital Management, LP 2seventy Bio, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.6 - $5.79 $90,579 - $145,682	25,161 New	25,161 $97,000
Q3 2023 Nov 09, 2023	SELL	$3.14 - $11.2 $211,752 - $755,294	-67,437 Reduced 4.63%	1,389,953 $5.45 Million
Q2 2023 Aug 10, 2023	BUY	$8.45 - $12.48 $3.62 Million - $5.35 Million	428,350 Added 41.63%	1,457,390 $14.7 Million
Q1 2023 May 11, 2023	BUY	$9.21 - $14.98 $1.12 Million - $1.83 Million	121,905 Added 13.44%	1,029,040 $10.5 Million
Q4 2022 Feb 13, 2023	BUY	$8.57 - $17.0 $5.68 Million - $11.3 Million	662,390 Added 270.64%	907,135 $8.5 Million
Q3 2022 Nov 10, 2022	SELL	$12.56 - $17.54 $315,683 - $440,850	-25,134 Reduced 9.31%	244,745 $3.56 Million
Q2 2022 Aug 19, 2022	BUY	$10.55 - $18.81 $382,901 - $682,690	36,294 Added 15.54%	269,879 $3.56 Million
Q1 2022 May 13, 2022	BUY	$11.67 - $26.72 $1.22 Million - $2.8 Million	104,699 Added 81.23%	233,585 $3.99 Million
Q4 2021 Feb 11, 2022	BUY	$13.77 - $42.56 $1.77 Million - $5.49 Million	128,886 New	128,886 $3.3 Million

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $123M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.